Optimistic Growth Prospects for Gilead Sciences: Buy Rating Backed by HIV and Oncology Advancements

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at $130.00.

Chris Schott has given his Buy rating due to a combination of factors that highlight the potential for Gilead Sciences’ stock to appreciate. A key element in this positive outlook is the anticipated launch of lenacapavir for PrEP, which is expected to significantly boost the company’s HIV portfolio. This launch, coupled with the ongoing advancement of various HIV treatment combinations, positions Gilead well for future growth in this segment.
Moreover, Gilead’s oncology portfolio, although still developing, shows promise with the expansion of the CART franchise and Trodelvy into new indications. The company’s strong cash flow generation also provides opportunities for strategic acquisitions and shareholder returns, further enhancing its growth prospects. These dynamics, along with effective cost management and a favorable market position with less tariff exposure compared to peers, underpin Schott’s optimistic view on Gilead’s stock.

In another report released on April 2, Bernstein also maintained a Buy rating on the stock with a $120.00 price target.